VK
Publicaties op Oncologisch.com
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monothera...
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Lenvatinib plus pembrolizumab versus sunitinib bij mRCC: CLEAR definitieve OS
Durvalumab plus olaparib bij onbehandeld platina-ineligibel urotheelcarcinoom
Lenvatinib plus pembrolizumab of everolimus bij gevorderd RCC: CLEAR/KEYNOTE-581 fase III